FUJIFILM Irvine Scientific Rebrands as FUJIFILM Biosciences

On Jan. 5, 2026, the Fujifilm Life Sciences Group announced that FUJIFILM Irvine Scientific has been officially rebranded as FUJIFILM Biosciences, as of Jan. 1, 2026 (1). The company has been providing cell culture solutions, such as of cell culture media, feeds, specialty chemicals and reagents, single-use technologies, and human-induced pluripotent stem cell capabilities for the life sciences market for 55 years, and the name change better aligns with the company’s history.

“All of us at FUJIFILM Biosciences take immense pride in being a people-focused company that empowers our colleagues to create an exceptional customer experience,” said Brandon Pence, president and chief operating officer, FUJIFILM Biosciences, in a press release (1). “We utilize our 55-year legacy of deep industry knowledge to collaboratively develop innovative solutions and technologies that are supplied from our global network of manufacturing facilities. With this approach and our ongoing investments, we look ahead to a strong future with our employees, customers, and partners around the world.”

What does the future hold for FUJIFILM Biosciences?

Pence spoke with the editors of PharmTech Group in June 2025 in advance of BIO 2025 about the future of the company (2).

“I think it's impressive when you look back over the last 15 years of the entrance into life sciences that FUJIFILM has made, and then the investment that has continued, and will continue into the future around how we add value in this space," Pence said in the interview. "Organically building out manufacturing facilities and supply chain routes to our customers across three different critical geographies has been an important part to how we've driven success and how we see the future shaping up.

“One of the areas that I think is impressive about the investment at FUJIFILM is in looking at areas that add value and have a direct impact on the quality of biologics that are being manufactured. Looking at cell culture and the business that was acquired in 2018 and now into the bio CDMO space, when you think about biologics, the cell itself is the therapy, or it's producing the therapy. And so, FUJIFILM has taken an approach of what is driving improvements in, and the quality of, the biologic coming out of the process, and then ultimately ending up with patients.”

How has FUJIFILM expanded its offerings?

FUJIFILM made some significant investments in 2025. In April 2025, FUJIFILM Biotechnologies signed an agreement with Regeneron for more than $3 billion to provide production of Regeneron’s products for a period of 10 years at its large-scale manufacturing facility in North Carolina, which the company planned to expand to accommodate the agreement.

“As the United States is the largest market for biopharmaceuticals, FUJIFILM Corporation has made significant investments in the US of about $4 billion in building world-class biopharmaceutical manufacturing sites, life sciences capabilities, and growing its technical talent,” Toshihisa Iida, director, corporate vice president, general manager of Life Sciences Strategy Headquarters and Bio-CDMO Division, FUJIFILM Corporation, Japan, said in a press release about the deal (3). “Additionally, through our previously announced expansion efforts, we are pleased to share that we’ve already added 500 new positions as part of our overall goal of creating 1400 new jobs in North Carolina by 2031.”

“I think as you look at FUJIFILM going forward, our foundation is in the reagents, materials, and the processes that directly impact performance in bioprocessing,” Pence continued in the interview (2). “And as we look to the future, both organically and inorganically, investments that will continue to be in that space will add value to our customers. And then keeping in mind that we're looking at ways in which we can support them in the regions they're operating in or in the regions where their patients are. And so, you'll see manufacturing facilities across the entire organization in life sciences spanning Europe, the US, Asia Pacific, and beyond that. So, it's an exciting time to be a part of FUJIFILM, and I think that the areas that we're focused upon are truly being recognized by our customers.”

References

1. FUJIFILM. FUJIFILM Irvine Scientific Now Officially FUJIFILM Biosciences. Press Release. Jan. 5, 2026. https://fujifilmbiosciences.fujifilm.com/us/blog/fujifilm-irvine-scientific-now-officially-fujifilm-biosciences.html
2. Lavery, P. BIO 2025: Building Relationships Amid a Rebrand. BioPharmInternational.com. June 19, 2025. https://www.biopharminternational.com/view/bio-2025-building-relationships-amid-a-rebrand
3. FUJIFILM. FUJIFILM Biotechnologies and Regeneron Sign a 10-Year U.S. Manufacturing Agreement Valued at Over $3 Billion. Press Release. April 22, 2025. https://fujifilmbiotechnologies.fujifilm.com/about/news/fujifilm-diosynth-biotechnologies-and-regeneron-sign-10-year-us-manufacturing-agreement/